Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Price Target Cut to $135.00 by Analysts at BMO Capital Markets

Zimmer Biomet Holdings, Inc. (NYSE:ZBH) had its price objective decreased by BMO Capital Markets from $140.00 to $135.00 in a research note released on Thursday, November 2nd. BMO Capital Markets currently has an outperform rating on the medical equipment provider’s stock.

ZBH has been the topic of several other research reports. Stifel Nicolaus reissued a hold rating and issued a $125.00 target price on shares of Zimmer Biomet Holdings in a research note on Friday, July 14th. Gabelli assumed coverage on Zimmer Biomet Holdings in a research note on Thursday, August 24th. They issued a buy rating and a $142.00 target price on the stock. Zacks Investment Research lowered Zimmer Biomet Holdings from a hold rating to a strong sell rating in a research note on Tuesday, August 8th. SunTrust Banks, Inc. reissued a buy rating and issued a $136.00 target price on shares of Zimmer Biomet Holdings in a research note on Monday, October 2nd. Finally, Wells Fargo & Company reaffirmed a market weight rating on shares of Zimmer Biomet Holdings in a research report on Friday, July 14th. Four analysts have rated the stock with a sell rating, seven have given a hold rating, fourteen have given a buy rating and one has issued a strong buy rating to the company’s stock. The stock has an average rating of Hold and a consensus target price of $133.71.

Zimmer Biomet Holdings (ZBH) opened at $111.06 on Thursday. The stock has a market capitalization of $22,423.90, a PE ratio of 13.72, a P/E/G ratio of 1.72 and a beta of 1.17. Zimmer Biomet Holdings has a 1-year low of $95.63 and a 1-year high of $133.49. The company has a quick ratio of 0.78, a current ratio of 1.47 and a debt-to-equity ratio of 0.88.

Zimmer Biomet Holdings (NYSE:ZBH) last posted its quarterly earnings results on Wednesday, November 1st. The medical equipment provider reported $1.72 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.74 by ($0.02). The firm had revenue of $1.82 billion during the quarter, compared to the consensus estimate of $1.83 billion. Zimmer Biomet Holdings had a net margin of 8.36% and a return on equity of 16.29%. Zimmer Biomet Holdings’s revenue was down .8% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.79 EPS. equities analysts forecast that Zimmer Biomet Holdings will post 8.03 EPS for the current year.

WARNING: This piece was originally reported by TrueBlueTribune and is the sole property of of TrueBlueTribune. If you are accessing this piece on another publication, it was copied illegally and reposted in violation of international copyright & trademark legislation. The legal version of this piece can be viewed at https://www.truebluetribune.com/2017/11/14/bmo-capital-markets-trims-zimmer-biomet-holdings-inc-zbh-target-price-to-135-00.html.

Hedge funds and other institutional investors have recently made changes to their positions in the business. BlackRock Inc. raised its holdings in shares of Zimmer Biomet Holdings by 4.1% during the 2nd quarter. BlackRock Inc. now owns 17,419,463 shares of the medical equipment provider’s stock worth $2,236,657,000 after buying an additional 679,080 shares in the last quarter. Vanguard Group Inc. raised its holdings in shares of Zimmer Biomet Holdings by 2.6% during the 2nd quarter. Vanguard Group Inc. now owns 13,380,517 shares of the medical equipment provider’s stock worth $1,718,057,000 after buying an additional 339,106 shares in the last quarter. State Street Corp raised its holdings in shares of Zimmer Biomet Holdings by 2.4% during the 1st quarter. State Street Corp now owns 8,193,165 shares of the medical equipment provider’s stock worth $1,000,463,000 after buying an additional 191,747 shares in the last quarter. Longview Partners Guernsey LTD raised its holdings in shares of Zimmer Biomet Holdings by 17.7% during the 3rd quarter. Longview Partners Guernsey LTD now owns 7,506,684 shares of the medical equipment provider’s stock worth $878,958,000 after buying an additional 1,128,973 shares in the last quarter. Finally, Nordea Investment Management AB raised its holdings in shares of Zimmer Biomet Holdings by 7.3% during the 3rd quarter. Nordea Investment Management AB now owns 5,277,660 shares of the medical equipment provider’s stock worth $617,961,000 after buying an additional 357,302 shares in the last quarter. 85.44% of the stock is owned by hedge funds and other institutional investors.

About Zimmer Biomet Holdings

Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.

Analyst Recommendations for Zimmer Biomet Holdings (NYSE:ZBH)

Receive News & Ratings for Zimmer Biomet Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply